Company profile

Xiling Lab Pharmaceutical Co., Ltd.is a new drug R & D company based in China and operating globally. Driven by innovation and cooperation, it provides safe and effective innovative drugs for patients in China and the world.

Xiling Lab Pharmaceutical Co., Ltd. was established in August 2016, owns Chengdu kelingyuan Pharmaceutical Technology Co., Ltd. and Guixi PharmaTech Pty Ltd. in Australia. Xiling Lab  has the qualification of "national high tech enterprise", and its core technology and management team have been awarded the title of "top innovation and entrepreneurship team" in Sichuan Province and Chengdu City.

Xiling Lab  is committed to building an internationally leading platform for small molecule drug concept validation, contrast agent drug development and catalytic technology. The company emphasizes practical innovation. At present, it has applied for more than 20 invention patents, of which 3 have completed the transfer of development rights, which has achieved considerable economic benefits for the company

Since its establishment, based on the concept of "win-win cooperation", the company has established partnership with a number of domestic and foreign biomedical enterprises to create a "global new" innovative drug product pipeline and "characteristic" series of contrast agent products. Among them, smp-100 for the treatment of irritable bowel syndrome has obtained the FDA clinical trial license, and is in the process of carrying out I-I in Australia A number of contrast media products have been verified and entered the application stage.

vision 愿景

Xiling Lab dedicates to create better clinic solutions for patients by innovating cutting-edge technologies.

Record of events

2020
In 2020, smp-100, the first innovative drug, was approved by FDA for clinical trial and successfully completed round a financing
Smp-100, a new class 1 drug developed by Chengdu kelingyuan Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Xiling Lab Pharmaceutical Co., Ltd., has successfully passed the new drug research application (ind) review of the US Food and Drug Administration (FDA), and is conducting phase I clinical trials abroad for the treatment of diarrhea predominant irritable bowel syndrome (IBS-D). We highly expect that it will relieve the pain of patients with diarrhea predominant irritable bowel syndrome (IBS-D) safely and effectively, and is expected to become the first effective drug for the treatment of alternating irritable bowel syndrome (ibs-m). The company has successfully completed a round of financing, with a total amount of RMB 50 million, laying a solid foundation for promoting the commercialization of the company.
2019
In 2019, it was recognized as a high-tech enterprise and won the title of "top innovation and entrepreneurship team" at provincial and municipal level
In October 2019, Xiling Lab was officially recognized as a national high-tech enterprise, which proves that the enterprise has strong technological innovation ability, high-end technology development ability and good potential economic benefits. In the same year, xilingyuan differentiated innovative drugs and major generic drugs team were selected as the "top innovation and entrepreneurship team" in Sichuan Province. The team members took advantage of their professional knowledge and pharmaceutical R & D experience, adhered to the innovation concept and actively promoted the industrial development.
2018
Undertaking provincial science and technology projects in 2018
Iopromide contrast agent is one of the most commonly used drugs in interventional radiology. It is mainly used for the display of blood vessels and body cavities. Iopropramide is mainly used for CT angiography, which belongs to class a of national medical insurance. The company's main R & D project "the development of the first generic drug X-ray contrast agent iopromide" was supported by Sichuan Science and technology plan in 2018, and two patents have been applied for this project.
2017
Visit of consynance in 2017
In June 2017, Dr. Peter guzzo and Dr. president Chuang Liu, CEO of consynance biotechnology company of the United States, visited xilingyuan for in-depth communication on some of the agonist development projects of serotonin (5-HT3). In 2017, the angel round financing of RMB 16.2 million was successfully completed, which will mean that xilingyuan is gradually growing.